Alzheimer’s Prevention Initiative in Colombia ADAD trial
Official title: Alzheimer's Prevention Initiative ADAD Colombia Trial Program
Funded at Banner Health · NIH-11600238 · Data updated 2026-11-12
A study in Colombia aims to test ideas to prevent Alzheimer’s in people who carry a genetic mutation that almost guarantees they will develop the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Banner Health NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $351,021 |
| NIH project number | 3R01AG086363-03S1 |
| Project ID | NIH-11600238 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals with the PSEN1 E280A mutation or other high-risk members in the ADAD Colombia kindred who are early in the disease trajectory or at risk but not yet severely impaired.
✕Less likely to help
Individuals without the ADAD genetic risk or with established dementia are unlikely to benefit from a preventive strategy studied here.
What this research studies
This project builds on a long-running program in a large Colombian family with a mutation that almost surely leads to Alzheimer’s. Researchers will use existing clinical, imaging, and biomarker infrastructure to follow carriers and potentially test preventive approaches as they approach age 40s and beyond. Families, clinicians, and researchers collaborate to track symptoms, brain changes, and biomarkers while exploring early-intervention strategies. The goal is to develop safe and effective ways to delay or prevent cognitive decline in those at high risk for Alzheimer’s disease. The study emphasizes ethical and social considerations, and aims to share findings that could inform prevention efforts worldwide.
Why it matters
Potential benefit: If successful, this work could lead to preventive strategies that delay or reduce Alzheimer’s symptoms for people at high genetic risk.
How similar studies have gone: Prior prevention trials in related AD contexts have shown biomarker changes and some clinical benefits, supporting the potential for preventive approaches to work.
Where this research is happening
-
Banner Health
Phoenix, United States Active
Researchers
- Principal investigator: Alexander, Robert C — Banner Health
- Study coordinator: Alexander, Robert C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.